| 0 Produits | - | CHF 0.00 |
| Ajouter au panier | ||
The gut microbiota is not only the biological interface between the immune, metabolic, and endocrine systems but also an important interface between the external environment and bone health. This is supported by a vast number of scientific evidence, and some of them are nicely summarized in the recently published literature review by Tornatore.7
Changes in the composition or function of the usual microbiota can lead to dysbiosis. This microbial imbalance causes damage to the epithelial barrier, our inner skin, resulting in pathogenic colonization and inflammation. This inflammatory response in the gut will send signals to the bone marrow (primary producer of blood cells), which in turn will stimulate osteoclast formation (cells responsible for degrading the bone) and reduce the synthesis of osteoblast (cells responsible for building the bone), thereby affecting bone health.
Several studies have shown that beneficial bacteria in the gut produce factors that modulate the immune response, help maintain gut barrier integrity, and help defend against pathogenic microorganisms. L. reuteri ATCC PTA 6475 is a beneficial bacteria that has a potential anti-inflammatory effect and helps to prevent damage to the epithelial barrier. Several studies carried on in the laboratory showed that L. reuteri ATCC PTA 6475 improves bone density in mice,9 prevents bone loss in a postmenopausal ovariectomized mouse model8 and prevents bone loss in mice with type 1 diabetes.10
Furthermore, a recent clinical study showed that daily supplementation of L. reuteri ATCC PTA 6475 for 12 months reduced bone loss by 50% in elderly women with low bone mineral density compared to placebo.6
All these studies suggest that L. reuteri ATCC PTA 6475 may have a preventive effect on bone health and pave the way for further research in this area.
Osteomicrobiology – Current literature review